News Agency
The Times

  • Written by PR Newswire

We are advised by NeuroGen that journalists and other readers should disregard the news release, China's First CGRP Targeted Therapy to Enter the NRDL: NeuroGen Officially Launches Ajovy® (fremanezumab), Benefiting the First Cohort of Migraine Patients, issued 18-Nov-2026 over PR Newswire. The release has been withdrawn following a change to the issuer's distribution arrangements.

Read more https://en.prnasia.com/story/archive/5101067_AE01067_0

Selecting Steel Plate for Industrial and Fabrication Projects

Start with the job requirements A successful fabrication project starts with material that suits the work it must perform. Choosing steel plate involves more than selecting a thickness from a stock list. Designers and procurement teams need to consider the load... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion